STOCK TITAN

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
conferences earnings

Panbela Therapeutics, Inc. (OTCQB: PBLA) will host a conference call on May 15, 2024, to discuss the results of its first quarter ended March 31, 2024. The call will focus on the company's disruptive therapeutics for urgent unmet medical needs.

Panbela Therapeutics, Inc. (OTCQB: PBLA) terrà una conferenza telefonica il 15 maggio 2024 per discutere i risultati del primo trimestre conclusosi il 31 marzo 2024. La chiamata si concentrerà sulle terapie innovative dell'azienda per esigenze mediche urgenti e non soddisfatte.
Panbela Therapeutics, Inc. (OTCQB: PBLA) organizará una llamada de conferencia el 15 de mayo de 2024 para discutir los resultados del primer trimestre que finalizó el 31 de marzo de 2024. La llamada se centrará en las terapias disruptivas de la compañía para necesidades médicas urgentes que no están cubiertas.
Panbela Therapeutics, Inc. (OTCQB: PBLA)는 2024년 3월 31일에 종료된 첫 번째 분기의 결과를 논의하기 위해 2024년 5월 15일에 컨퍼런스 콜을 개최할 예정입니다. 전화 회의는 회사의 혁신적인 치료법에 집중할 것입니다. 이 치료법은 긴급하게 충족되지 않은 의료 필요를 위한 것입니다.
Panbela Therapeutics, Inc. (OTCQB: PBLA) organisera une conférence téléphonique le 15 mai 2024 pour discuter des résultats de son premier trimestre qui s'est terminé le 31 mars 2024. L'appel se concentrera sur les thérapeutiques novatrices de l'entreprise pour des besoins médicaux urgents non satisfaits.
Panbela Therapeutics, Inc. (OTCQB: PBLA) wird am 15. Mai 2024 eine Telefonkonferenz abhalten, um die Ergebnisse des ersten Quartals, das am 31. März 2024 endete, zu besprechen. Das Gespräch wird sich auf die disruptiven Therapien des Unternehmens für dringende, unerfüllte medizinische Bedürfnisse konzentrieren.
Positive
  • None.
Negative
  • None.

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.

Conference Call Information

Toll Free: 877-545-0523
International: 973-528-0016
Participant Access Code: 234396
Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531

Conference Call Replay Information

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 50531
Webcast Replay: https://www.webcaster4.com/Webcast/Page/2556/50531

About Panbela’s Pipeline
The pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer. The combined development programs have a steady cadence of anticipated catalysts with programs ranging from pre-clinical to registration studies.

Ivospemin (SBP-101)
Ivospemin is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. It has shown signals of tumor growth inhibition in clinical studies of metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 14.6 months and an objective response rate (ORR) of 48%, both exceeding what is typical for the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, ivospemin has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the previous Panbela-sponsored clinical trials provide support for continued evaluation of ivospemin in the ASPIRE trial.

Flynpovi ™
Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. In a Phase III clinical trial in patients with sporadic large bowel polyps, the combination prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo. Focusing on FAP patients with lower gastrointestinal tract anatomy in the recent Phase III trial comparing Flynpovi to single agent eflornithine and single agent sulindac, FAP patients with lower GI anatomy (patients with an intact colon, retained rectum or surgical pouch), showed statistically significant benefit compared to both single agents (p≤0.02) in delaying surgical events in the lower GI for up to four years. The safety profile for Flynpovi did not significantly differ from the single agents and supports the continued evaluation of Flynpovi for FAP.

CPP-1X
CPP-1X (eflornithine) is being developed as a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes. Preclinical studies as well as Phase I or Phase II investigator-initiated trials suggest that CPP-1X treatment may be well-tolerated and has potential activity.

About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP-101) and Flynpovi. Further information can be found at www.panbela.com. Panbela’s common stock is eligible for quotation on the OTCQB under the symbol “PBLA”.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “can,” “design,” “expect,” “focus,” “intend,” “looking forward,” “may,” “plan,” “positioned,” “potential,” and “will.” All statements other than statements of historical fact are statements that should be deemed forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to execute our business and clinical development plans; (ii) progress and success of our clinical development program; (iii) the impact of the current COVID-19 pandemic on our ability to conduct our clinical trials; (iv) our ability to demonstrate the safety and effectiveness of our product candidates: ivospemin (SBP-101) and eflornithine (CPP-1X); (v) our reliance on a third party for the execution of the registration trial for our product candidate Flynpovi ; (vi) our ability to obtain regulatory approvals for our product candidates, SBP-101 and CPP-1X in the United States, the European Union or other international markets; (vii) the market acceptance and level of future sales of our product candidates, SBP-101 and CPP-1X; (viii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our product candidates, SBP-101 and CPP-1X; (ix) the rate of progress in establishing reimbursement arrangements with third-party payors; (x) the effect of competing technological and market developments; (xi) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; (xii) our ability to obtain a listing of our common stock on a national securities exchange; and (xii) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com

Media:
Tammy Groene
Panbela Therapeutics, Inc.
(952) 479-1196
IR@panbela.com


FAQ

When will Panbela host the conference call to discuss its first quarter 2024 results?

Panbela will host the conference call on May 15, 2024, at 4:30 PM Eastern Time.

What is the Participant Access Code for the conference call?

The Participant Access Code for the conference call is 234396.

Where can I find the webcast link for the conference call?

The webcast link for the conference call is https://www.webcaster4.com/Webcast/Page/2556/50531.

What is the Replay Passcode for the conference call replay?

The Replay Passcode for the conference call replay is 50531.

PANBELA THERAPEUTICS INC

OTC:PBLA

PBLA Rankings

PBLA Latest News

PBLA Stock Data

1.55M
4.85M
0%
3.07%
Biotechnology
Healthcare
Link
United States of America
Waconia